Evofem Biosciences, Inc. (EVFM) Form 8-K — Oct 15, 2026

Evofem Biosciences entered a fifth amendment to its Securities Purchase Agreement with Adjuvant Global Health Technology Fund entities on October 9, 2026, originally dated October 14, 2020 for convertible promissory notes. The amendment makes the Notes due and payable in full on the earliest of December 1, 2026, a Change of Control at Adjuvant's election, or any acceleration, and bars prepayment before December 1, 2026 without Adjuvant's written consent.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.